OBJECTIVE: To systematically review the clinical efficacy and safety evidence of biologic
drugs used to treat the polyarticular category of juvenile idiopathic arthritis (JIA). METHODS …

Objective To establish the safety and efficacy of infliximab for the treatment of refractory
noninfectious uveitis. Design Retrospective, interventional, noncomparative cohort study …

Biologics have advanced the therapy of adult and pediatric arthritis. They have been linked
to rare serious adverse outcomes, but the actual risk of these events is controversial in …

Objective Juvenile idiopathic arthritis (JIA) is the most common chronic pediatric rheumatic
disease and can have long‐term effects leading to disability in adulthood. Biologics are a …

Objective. To describe infusion reactions (IR) and severe adverse events (SAE) associated
with infliximab (IFX) in pediatric patients with rheumatologic and ocular inflammatory …

Juvenile idiopathic arthritis (JIA) is one of the most common chronic rheumatic diseases in
children. The estimated prevalence of the disease varies considerably, ranging from 7 to …

Een 35-jarige man zonder psychiatrische voorgeschiedenis kreeg dwangklachten na een
dosisverhoging van infliximab, voorgeschreven als behandeling voor de ziekte van Crohn …

L'arthrite juvénile idiopathique (AJI) est un groupe hétérogène de rhumatismes
inflammatoires chroniques ayant en commun un âge de début avant 18 ans, une durée …

Headache is the more often seen complaint in patient with rheumatoid arthritis (RA) at the
visit to the neurologist. The objective of this study is analysis of headaches in children with …

Juvenile idiopathic arthritis is a constellation of heterogeneous forms of arthritis that develop in
pediatric patients younge Page 1 The Hospital for Sick Children Technology Assessment at …